Rifampicin

Generic Name: Rifampicin

Brand Names: Isonarif, Rifadin, Rifamate, Rifater, Rofact

Drug Type: Small Molecule

Chemical Formula: C_₄₃H_₅₈N_₄O_₁₂

CAS Number: 13292-46-1

Unique Ingredient Identifier: VJT6J7R4TR

Background: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)

Indication: Rifampin is indicated for the treatment of tuberculosis and tuberculosis-related mycobacterial infections. In combination with pyrazinamide and isoniazid, it is used in the initial phase of the short-course treatment of pulmonary tuberculosis.

Associated Conditions: Cholestatic pruritus, MRSA Infections, Prosthetic Joint Infections, Asymptomatic Neisseria meningitidis carrier of the nasopharynx, Initial phase Tuberculosis, Late phase Tuberculosis

Associated Therapies: Antibacterial therapy

Clinical Trials

An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)

Phase 1

Completed

Conditions: Multiple Myeloma
Non-Hodgkin's Lymphoma

Interventions: Drug: bortezomib, rifampicin
Drug: bortezomib, dexamethasone
Drug: bortezomib

First Posted Date: 2008-02-06

Last Posted Date: 2012-01-30

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 61

Registration Number: NCT00608907

Locations: 🇮🇱
Hematology Institute - Davidoff Center - Rabin Medical Center, Petach Tikva, Israel
🇵🇱
Medical Academy - Dept of Hematology and Transplantology, Gdansk, Poland
🇬🇧
Hematology Department Combined Laboratories - Derriford Hospital, Plymouth, United Kingdom

and more 6 locations

A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

Phase 1

Completed

Conditions: Non-Small Cell Lung Cancer ALK-positive
Systemic Anaplastic Large-Cell Lymphoma
Non-Small Cell Lung Cancer c-Met Dependent
Non-Small Cell Lung Cancer ROS Marker Positive
Advanced Malignancies Except Leukemia

Interventions: Drug: PF-02341066
Drug: Rifampin
Drug: Itraconazole

First Posted Date: 2008-01-03

Last Posted Date: 2023-02-08

Lead Sponsor: Pfizer

Target Recruit Count: 596

Registration Number: NCT00585195

Locations: 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
The James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States

and more 25 locations

Controlled Trial: 5-day Course of Rifampin Versus Doxycycline for the Treatment of Mild to Moderate Scrub Typhus

Not Applicable

Completed

Conditions: Scrub Typhus

Interventions: Drug: doxycycline
Drug: rifampin

First Posted Date: 2007-12-06

Last Posted Date: 2019-02-08

Lead Sponsor: Dong-Min Kim

Target Recruit Count: 476

Registration Number: NCT00568711

Locations: 🇰🇷
Chosun University Hospital, Gwangju, Jeonnam, Korea, Republic of

A Study of the Interaction of Rifampin and Vinflunine in Subjects With Advanced Cancer

Phase 1

Withdrawn

Conditions: Cancer

First Posted Date: 2007-09-26

Last Posted Date: 2015-09-01

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT00534807

Locations: 🇺🇸
Local Institution, Detroit, Michigan, United States

Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146 CARINEMO)

Phase 2

Completed

Conditions: Tuberculosis
Aids
Hiv Infections

Interventions: Drug: Nevirapine based therapy
Drug: Efavirenz based therapy
Drug: Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z)

First Posted Date: 2007-07-03

Last Posted Date: 2012-02-15

Lead Sponsor: French National Agency for Research on AIDS and Viral Hepatitis

Target Recruit Count: 570

Registration Number: NCT00495326

Locations: 🇲🇿
Health centre of Josue Macao, Maputo, Mozambique
🇲🇿
Health centre of Malavane, Maputo, Mozambique
🇲🇿
Health centre of Alto Mae, Chamanculo district, Maputo, Mozambique